Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization’s database

Importance: Endocrine therapies (ETs) and inhibitors of cyclin-dependent kinases-4/6 (iCDK4/6s) are a standard treatment in breast cancer. However, data on potential neurocognitive impacts remain inconsistent for ET and are scarce for iCDK4/6s. Objective: To evaluate whether ET and iCDK4/6s are asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Prevost, Rachel, Chretien, Basile, Minoc, Elise-Marie, Dolladille, Charles, Da-Silva, Angélique, Nehme, Ahmad, Joly, Florence, Lelong-Boulouard, Véronique, Bastien, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622981/
https://www.ncbi.nlm.nih.gov/pubmed/37927591
http://dx.doi.org/10.3389/fphar.2023.1278682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622981/
https://www.ncbi.nlm.nih.gov/pubmed/37927591
http://dx.doi.org/10.3389/fphar.2023.1278682

Ejemplares similares